Use_of_intravenous_immunoglobulin_in_chronic_lymphocytic_leukemia._A_brief_review._Chronic_lymphocytic_leukemia_(CLL)_is_a_disorder_with_multiple_defects_leading_to_an_increased_susceptibility_to_infection._Hypogammaglobulinemia_is_present_in_about_20%_to_70%_of_patients_with_CLL._Intravenous_immunoglobulin_(IVIG)_supplementation_(400_mg/kg_body_weight_every_3_weeks)_prevented_bacterial_infections_in_these_patients._An_ongoing_study_is_being_conducted_to_compare_doses_of_250_mg/kg/mo_with_those_of_500_mg/kg/mo_in_36_patients_included_so_far._As_of_this_writing,_the_rate_of_infection_in_the_two_treatment_groups_was_not_significantly_different,_and_no_substantial_loss_of_protection_against_bacterial_infection_was_found_in_the_lower-dose_group._It_seems_likely_that_the_lower_dose_is_almost_as_effective_as_the_standard_therapy._If_this_is_so,_cost_savings_would_be_substantial.